Complete Story


SAMHSA issues guidance on use of injectable naltrexone

The Substance Abuse and Mental Health Services Administration (SAMHSA) has issued new guidance on the clinical use of extended-release injectable naltrexone for treatment of opioid use disorder. Clinical Use of Extended-Release Injectable Naltrexone in the Treatment of Opioid Use Disorder: A Brief Guideis based on a review of the current evidence on the effectiveness of available medications for the treatment of opioid use disorders, including a summary of the key differences between extended-release injectable naltrexone, methadone, and buprenorphine. The guidance provides key information on assessing the patient’s need for treatment, and initiating medication-assisted treatment (MAT). It also advises on how to monitor patient progress, adjust the treatment plan, and decide whether and when to end MAT.


Source: Ohio Department of Mental Health and Addiction Services

Printer-Friendly Version